文献速递前列腺癌

利用循环肿瘤细胞无创检测临床显著性前列腺癌

Noninvasive Detection of Clinically Significant Prostate Cancer Using Circulating Tumor Cells.
PubMed 文献 · J Urol · 2019-08-07

研究纳入155例初治前列腺癌患者和98例活检前患者,检测循环肿瘤细胞并分析其基因表达。局限型前列腺癌中54%循环肿瘤细胞阳性,与更高Gleason评分、风险组和临床显著性前列腺癌相关。活检前组中循环肿瘤细胞评分联合前列腺特异性抗原预测临床显著性前列腺癌的AUC为0.869,联合12基因面板后AUC为0.927,联合多参数磁共振数据后预测准确率显著提高(AUC 0.936 vs 0.629)。

要点

  • 局限型前列腺癌中54%循环肿瘤细胞阳性,与更高Gleason评分和风险组相关。
  • 活检前组循环肿瘤细胞评分联合前列腺特异性抗原预测临床显著性前列腺癌AUC 0.869。
  • 联合前列腺特异性抗原、循环肿瘤细胞评分和12基因面板的AUC为0.927。

核心结论

  • 循环肿瘤细胞分析有潜力通过前列腺特异性抗原和/或多参数磁共振成像显著改善活检和治疗的患者分层。

研究设计与样本

  • 研究纳入155例初治前列腺癌患者和98例活检前患者进行循环肿瘤细胞计数。
  • 从184例患者的循环肿瘤细胞中提取RNA进行基因表达分析。
  • 采用Kruskal-Wallis检验、Spearman秩检验、多变量逻辑回归和随机森林方法评估循环肿瘤细胞与侵袭性前列腺癌的关联。

主要发现

  • 局限型前列腺癌患者中54%被评分为循环肿瘤细胞阳性,与更高Gleason评分(p=0.0003)、风险组(p<0.0001)和临床显著性前列腺癌(p<0.0001)相关。
  • 活检前组中循环肿瘤细胞评分联合前列腺特异性抗原预测临床显著性前列腺癌的AUC为0.869。
  • 鉴定出一个预后临床显著性前列腺癌的12基因面板。
  • 联合前列腺特异性抗原水平、循环肿瘤细胞评分和12基因面板时,临床显著性前列腺癌预测的AUC为0.927。
  • 将上述数据加入有多参数磁共振成像数据的病例中,显著提高预测准确率(AUC 0.936 vs 0.629)。

关键数值与推荐

  • 局限型前列腺癌患者中循环肿瘤细胞阳性率为54%。
  • 循环肿瘤细胞阳性与更高Gleason评分相关(p=0.0003)。
  • 循环肿瘤细胞阳性与更高风险组相关(p<0.0001)。
  • 循环肿瘤细胞阳性与临床显著性前列腺癌相关(p<0.0001)。
  • 活检前组中循环肿瘤细胞评分联合前列腺特异性抗原预测临床显著性前列腺癌的AUC为0.869。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prostate specific antigen testing results in unnecessary biopsy and over diagnosis with consequent overtreatment. Tissue biopsy is an invasive procedure associated with significant morbidity. More accurate noninvasive or minimally invasive diagnostic approaches should be developed to avoid unnecessary prostate biopsy and over diagnosis. We investigated the potential of using circulating tumor cell analysis in cancer diagnosis, particularly to predict clinically significant prostate cancer in prebiopsy cases. MATERIALS AND METHODS: We enrolled 155 treatment naïve patients with prostate cancer and 98 before biopsy for circulating tumor cell enumeration. RNA was extracted from circulating tumor cells of 184 patients for gene expression analysis. The Kruskal-Wallis and Spearman rank tests, multivariate logistic regression and the random forest method were applied to assess the association of circulating tumor cells with aggressive prostate cancer. RESULTS: Of patients with localized prostate cancer 54% were scored as having positive circulating tumor cells, which was associated with a higher Gleason score (p=0.0003), risk group (p <0.0001) and clinically significant prostate cancer (p <0.0001). In the prebiopsy group a positive circulating tumor cell score combined with prostate specific antigen predicted clinically significant prostate cancer (AUC 0.869). A 12-gene panel prognostic for clinically significant prostate cancer was also identified. When combining the prostate specific antigen level, the circulating tumor cell score and the 12-gene panel, the AUC of clinically significant prostate cancer prediction was 0.927. Adding those data to cases with available multiparametric magnetic resonance imaging data significantly increased prediction accuracy (AUC 0.936 vs 0.629). CONCLUSIONS: Circulating tumor cell analysis has the potential to significantly improve patient stratification by prostate specific antigen and/or multiparametric magnetic resonance imaging for biopsy and treatment.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Xu L, Mao X, Grey A, et al. Noninvasive Detection of Clinically Significant Prostate Cancer Using Circulating Tumor Cells. J Urol. 2019. PMID: 31389764. doi:10.1097/JU.0000000000000475

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。